BeiGene Accelerates Global Momentum with Strong Second Quart

BASEL, Switzerland, BEIJING, & CAMBRIDGE, Mass., August 02, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the second quarter of 2023 and business highlights.

Related Keywords

Beijing , China , Australia , Canada , Suzhou , Jiangsu , Cambridge , Cambridgeshire , United Kingdom , Japan , United States , Guangzhou , Guangdong , America , American , Johnv Oyler , Luye Pharma , Liza Heapes , European Hematology Association , Beigene Ltd , Australia Therapeutic Goods Administration , Genentech Inc , Health Canada , Development Programs , Committee For Medicinal Products Human Use , Dmax Foundation , China National Medicinal Products Administration , Amgen , Luye Pharma Group Ltd , Exchange Commission , Drug Administration , Novartis , European Medicines Agency , European Society Of Medical Oncology , Scientific Congress Updates , American Society Of Clinical Oncology , Beigene Foundation , Business Wire , Medicinal Products , Human Use , Prescription Drug User Fee Act , Antibody Drug Conjugate , American Depositary Share , Cash Equivalents , Restricted Cash , Short Term Investments , Second Quarter , Quarterly Report , Goserelin Microspheres , Lung Cancer , Solid Tumor , European Society , Medical Oncology , Annual Meeting , American Society , Clinical Oncology , Princeton West Innovation Campus , License Agreement , North America , Condensed Consolidated Balance Sheet Data , Consolidated Statements , American Depositary Shares , Condensed Consolidated Financial Statements , Significant Accounting , Prior Period Financial , Private Securities Litigation Reform Act , Luye Pharma Group , Adult Patients , Beigene , Global Biotechnology Company , Wall ,